Pay in 4 interest-free payments of $5.82 Learn more
Ships within 48 hours · Estimated delivery Oct 30 - Nov 4
In the SURPASS clinical trial program, tirzepatide reduced HbA1c by 2.0-2.4% depending on dose, bringing the majority of participants to target levels below 7.0%
Taking GLP-1 Complete while continuing to eat highly processed foods in large quantities is unlikely to produce meaningful results regardless of what the gut microbiome does
The post says clinical studies show GLP-1 agonists lower HbA1c by 0.8 to 1.8 percent in patients with diabetes and produce weight loss of 5 to 15 percent in weight management use
The de-identified participant data will be made available to researchers whose proposals meet the research criteria and other conditions, and for which an exception does not apply, via a secure portal
To view or add a comment, sign in Decoding VCT220 (CX11, gimaglipron): China's Oral GLP-1 Contender Alongside Orforglipron and HRS-7535 Following positive Phase 3 topline results in Chinese adults with obesity, VCT220 (Gimaglipron, CX11), discovered by Vincentage Pharma and now being developed globally by CORXEL Pharmaceuticals, has emerged as one of China's leading oral small-molecule GLP-1 receptor agonists, with NDA submission planned for obesity and potential expansion into type 2 diabetes
